Gu C - Search Results

1

CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma.

Han SS, Tompkins VS, Son DJ, Han S, Yun H, Kamberos NL, Dehoedt CL, Gu C, Holman C, Tricot G, Zhan F, Janz S. Han SS, et al. Among authors: gu c. Exp Hematol Oncol. 2015 Mar 27;4:9. doi: 10.1186/s40164-015-0005-2. eCollection 2015. Exp Hematol Oncol. 2015. PMID: 25838973 Free PMC article.

2

FOXM1 is a therapeutic target for high-risk multiple myeloma.

Gu C, Yang Y, Sompallae R, Xu H, Tompkins VS, Holman C, Hose D, Goldschmidt H, Tricot G, Zhan F, Janz S. Gu C, et al. Leukemia. 2016 Apr;30(4):873-82. doi: 10.1038/leu.2015.334. Epub 2015 Dec 9. Leukemia. 2016. PMID: 26648534 Free PMC article.

3

Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma.

Gu C, Jing X, Holman C, Sompallae R, Zhan F, Tricot G, Yang Y, Janz S. Gu C, et al. BMC Cancer. 2018 Nov 21;18(1):1152. doi: 10.1186/s12885-018-5015-0. BMC Cancer. 2018. PMID: 30463534 Free PMC article.

4

HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA.

Jiang F, Tang X, Tang C, Hua Z, Ke M, Wang C, Zhao J, Gao S, Jurczyszyn A, Janz S, Beksac M, Zhan F, Gu C, Yang Y. Jiang F, et al. Among authors: gu c. J Hematol Oncol. 2021 Apr 1;14(1):54. doi: 10.1186/s13045-021-01066-6. J Hematol Oncol. 2021. PMID: 33794982 Free PMC article.

5

Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma.

Gu C, Jing X, Holman C, Sompallae R, Zhan F, Tricot G, Yang Y, Janz S. Gu C, et al. BMC Cancer. 2019 Dec 20;19(1):1238. doi: 10.1186/s12885-019-6443-1. BMC Cancer. 2019. PMID: 31862002 Free PMC article.

6

Chromosomal instability and acquired drug resistance in multiple myeloma.

Wang W, Zhang Y, Chen R, Tian Z, Zhai Y, Janz S, Gu C, Yang Y. Wang W, et al. Among authors: gu c. Oncotarget. 2017 Sep 11;8(44):78234-78244. doi: 10.18632/oncotarget.20829. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100463 Free PMC article. Review.

7

Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome.

Gu C, Holman C, Sompallae R, Jing X, Tomasson M, Hose D, Seckinger A, Zhan F, Tricot G, Goldschmidt H, Yang Y, Janz S. Gu C, et al. Blood Cancer J. 2018 Feb 15;8(2):22. doi: 10.1038/s41408-018-0060-0. Blood Cancer J. 2018. PMID: 29449574 Free PMC article. No abstract available.

8

CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone lesion formation in multiple myeloma.

Gu C, Wang W, Tang X, Xu T, Zhang Y, Guo M, Wei R, Wang Y, Jurczyszyn A, Janz S, Beksac M, Zhan F, Seckinger A, Hose D, Pan J, Yang Y. Gu C, et al. Mol Cancer. 2021 Jun 5;20(1):84. doi: 10.1186/s12943-021-01380-0. Mol Cancer. 2021. PMID: 34090465 Free PMC article.

9

RFWD2 induces cellular proliferation and selective proteasome inhibitor resistance by mediating P27 ubiquitination in multiple myeloma.

Gu C, Lu T, Wang W, Shao M, Wei R, Guo M, Li R, Qiao L, Hu Y, Zhan F, Seckinger A, Hose D, Yang Y. Gu C, et al. Leukemia. 2021 Jun;35(6):1803-1807. doi: 10.1038/s41375-020-01033-z. Epub 2020 Sep 8. Leukemia. 2021. PMID: 32901100 No abstract available.

10

Suppression of steroid 5α-reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma.

Dou R, Qian J, Wu W, Zhang Y, Yuan Y, Guo M, Wei R, Yang S, Jurczyszyn A, Janz S, Beksac M, Gu C, Yang Y. Dou R, et al. Among authors: gu c. Cell Death Dis. 2021 Feb 24;12(2):206. doi: 10.1038/s41419-021-03510-4. Cell Death Dis. 2021. PMID: 33627630 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,935 results

Search Page

Filters